Sionna Stock
HealthTechLooking to sell Sionna stock or options?
Sionna is a life sciences technology developer focused on creating highly effective and distinct treatments for cystic fibrosis. The company is advancing first-in-class small molecules targeting a unique pathway, aiming to fully normalize cystic fibrosis transmembrane conductance regulator (CFTR) function for the vast majority of those affected by the condition. Sionna's approach promises best-in-class efficacy, broad reach, and sustained benefits for cystic fibrosis patients.
Investors Include:
Qatar Investment Authority, Enavate Sciences, Viking Global Investors, Atlas Venture, Perceptive Advisors, OrbiMed, AbbVie Ventures, TPG, T. Rowe Price Group, RA Capital Management, Cystic Fibrosis Foundation.